CD4BS CH505M5 Pr-NP1

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Phase 1

Withdrawn

Interventions: Biological: CD4BS CH505M5 Pr-NP1
Biological: CH505TF chTrimer
Biological: ACU-026-001-1 (labeled as empty LNP)
Biological: 3M-052-AF (labeled as AP 60-702)
Biological: Aluminum Hydroxide Suspension (Alum)

Locations: 🇺🇸
Alabama CRS (Site ID: 31788), Birmingham, Alabama, United States
🇺🇸
The Ponce de Leon Center CRS (Site ID: 5802), Atlanta, Georgia, United States
🇺🇸
Vanderbilt Vaccine (VV) CRS (Site ID: 30352), Nashville, Tennessee, United States

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.